Skip to main content
. Author manuscript; available in PMC: 2018 Dec 28.
Published in final edited form as: Sci Transl Med. 2014 Jun 25;6(242):242ra84. doi: 10.1126/scitranslmed.3008455

Figure 5. Dual COX-2/VEGF pathway blockade suppresses colon cancer liver metastasis.

Figure 5.

(A) HCT116 tumor growth rates in response to bevacizumab (Bev) and celecoxib (Cel). All treatments were initiated when tumors reached a size of ~100 mm3. N.S: Nonsignificant. P values for the other comparisons are provided in table S1.

(B) HCT116 tumor growth rates in response to axitinib and celecoxib (Cel). All treatments were initiated when tumors reached a size of ~100 mm3. N.S: Non-significant. P values for the other comparisons are provided in table S1.

(C) VEGFR2 immunoprecipitation followed by western blotting was used to assess the amount of phosphorylated VEGFR2 (p-VEGFR2) in tumors in vivo after treatment with celecoxib or axitinib.

(D) Bioluminescent imaging of tumor burden 14 days after intrasplenic injection of HCT116-luc cells, applying a maximum luminescence threshold of 1×1010.

(E) Quantification of tumor burden shown in (D). Celecoxib (Cel); Axitinib (Axit).

(F) Physical appearance of HCT116 tumor burden in the liver.

(G) Whole body bioluminescent quantification 14 days after intrasplenic injection of CT26-luc cells. The whole body data are comparable to bioluminescent quantification of ex vivo livers (see fig. S12C). Cel: Celecoxib; Axit: Axitinib.

Data are presented as mean ± SEM.